Skip to main content
Clinical Trials/NCT07389759
NCT07389759
Active, not recruiting
Not Applicable

Impact of CADx on Endoscopists' Histologic Characterization of Diminutive Colorectal Polyps

Shanghai Jiao Tong University School of Medicine1 site in 1 country363 target enrollmentStarted: January 3, 2026Last updated:

Overview

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Shanghai Jiao Tong University School of Medicine
Enrollment
363
Locations
1
Primary Endpoint
Pass rate for the "resect and discard" strategy

Overview

Brief Summary

This study evaluates the impact of CADx assistance on endoscopists' histologic characterization of diminutive colorectal polyps (≤5 mm) during colonoscopy. The primary objective is to determine whether CADx assistance increases the proportion of endoscopists who meet PIVI-related performance thresholds, thereby supporting implementation of the "resect and discard" and "diagnose and leave" strategies in routine clinical practice.

Detailed Description

This study evaluates the impact of CADx assistance on endoscopists' histologic characterization of diminutive colorectal polyps (≤5 mm) during colonoscopy. The primary objective is to determine whether CADx assistance increases the proportion of endoscopists who meet PIVI-related performance thresholds, thereby supporting implementation of the "resect and discard" and "diagnose and leave" strategies in routine clinical practice.

In this randomized controlled trial, endoscopists will be assigned to one of three arms: no CADx assistance, CADx assistance without predicted probability, or CADx assistance with predicted probability. The CADx system provides NICE-based histology predictions (Type 1 vs Type 2), which endoscopists may use to support optical diagnosis and subsequent management decisions, including surveillance interval recommendations when applicable. Outcomes will compare endoscopist-level pass rates and diagnostic performance metrics relevant to PIVI-based adoption, with histopathology as the reference standard where applicable.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Endoscopists with NBI experience

Exclusion Criteria

  • Endoscopists without colonoscopy and NBI experience

Arms & Interventions

Standard Colonoscopy (No CADx Assistance)

No Intervention

Endoscopists perform optical diagnosis of diminutive colorectal polyps (≤5 mm) during colonoscopy using narrow-band imaging (NBI) without any CADx assistance.

CADx Without Predicted Probability

Experimental

Endoscopists perform optical diagnosis of diminutive colorectal polyps (≤5 mm) during colonoscopy using NBI, with CADx-displayed NICE classification predictions but without any predicted probability information.

Intervention: CADx-Assisted Endoscopic Diagnosis System Without Predicted Probability Display (Device)

CADx With PPredicted Probability

Experimental

Endoscopists perform optical diagnosis of diminutive colorectal polyps (≤5 mm) during colonoscopy using NBI, with CADx-displayed NICE classification predictions and accompanying predicted probability information.

Intervention: CADx-Assisted Endoscopic Diagnosis System With Predicted Probability Display (Device)

Outcomes

Primary Outcomes

Pass rate for the "resect and discard" strategy

Time Frame: 14 days

Proportion of endoscopists who achieve ≥90% accuracy in correctly predicting the patient's recommended surveillance colonoscopy interval according to the 2020 U.S. Multi-Society Task Force (USMSTF) consensus recommendations.

Pass rate for the "diagnose and leave" strategy

Time Frame: 14 days

Proportion of endoscopists who achieve a negative predictive value (NPV) ≥90% for neoplastic lesions among rectosigmoid polyps, when predictions are made with high diagnostic confidence

Secondary Outcomes

  • Pass rate for the ESGE 2020-based "resect and discard" strategy(14 days)
  • Pass rate for the APWG 2022-based "resect and discard" strategy(14 days)
  • Pass rate for the China 2023-based "resect and discard" strategy(14 days)
  • SODA-1 achievement rate(14 days)
  • SODA-2 achievement rate(14 days)
  • Proportion of high-confidence optical diagnoses(14 days)
  • Accuracy of high-confidence optical diagnosis (neoplastic vs non-neoplastic)(14 days)

Investigators

Sponsor
Shanghai Jiao Tong University School of Medicine
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Xiaobo Li

Chief physician

Shanghai Jiao Tong University School of Medicine

Study Sites (1)

Loading locations...

Similar Trials